C1QB

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Lorvotuzumab mertansineBB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1Phase 2 ClinicalImmunogen IncRhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell
Details
CUBT-906CUBT-906Phase 2 ClinicalCurative Biotechnology IncGlioblastoma
Details
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/CD56Phase 2 ClinicalShenzhen Geno-Immune Medical InstituteNeoplasms
Details
IN-B015IN-B-015; IN-B00004Phase 1 ClinicalHK inno.N CorporationNeoplasms
Details
  • Product Inquiry
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8